



## **Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference**

November 24, 2020

DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS<sup>®</sup> genome editing platform, today announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will participate in a fireside chat at the Piper Sandler 32<sup>nd</sup> Annual Virtual Healthcare Conference, November 30 – December 3, 2020.

This fireside chat has been pre-recorded and is now available for registered attendees via the Piper Sandler conference site until December 3. It is also available on Precision's website, [www.PrecisionBiosciences.com](http://www.PrecisionBiosciences.com) in the Investors and Media section under Events and Presentations.

### **About Precision BioSciences, Inc.**

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS<sup>®</sup> genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit [www.precisionbiosciences.com](http://www.precisionbiosciences.com).

### **Investor Contact:**

Alex Kelly  
Chief Corporate Affairs Officer  
[Alex.Kelly@precisionbiosciences.com](mailto:Alex.Kelly@precisionbiosciences.com)